SM
TXMD icon

Sabby Management’s TherapeuticsMD TXMD Stock Holding History

Sabby Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5
Closed -$180K – 260
2017
Q1 		$180K Sell
5
-9
-64% -$2.79K 0.01% 220
2016
Q4 		$406K Sell
14
-24
-63% -$7.44K 0.02% 211
2016
Q3 		$1.3M Buy
38
+15
+65% +$5.48K 0.05% 163
2016
Q2 		$980K Buy
23
+13
+130% +$5.36K 0.05% 161
2016
Q1 		$327K Sell
10
-110
-92% -$37.5K 0.02% 239
2015
Q4 		$6.22M Sell
120
-76
-39% -$28.1K 0.34% 52
2015
Q3 		$5.74M Buy
196
+67
+52% +$23.8K 0.24% 72
2015
Q2 		$5.08M Buy
129
+59
+84% +$20.8K 0.19% 90
2015
Q1 		$2.11M Buy
70
+66
+1,650% +$16.1K 0.09% 141
2014
Q4 		$95 Buy
+4
New +$825 ﹤0.01% 221

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's TXMD Position: Q3 2021 in Review

Sabby Management sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 12,500 shares — an estimated $744K sold.

Sabby Management first reported a position in TXMD in Q2 2013 and held it in 8 quarters. The position peaked at $1.07M in Q1 2021. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • Sabby Management reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
  • Sabby Management sold 12,500 TherapeuticsMD shares in Q3 2021, an estimated $744K.
  • Sabby Management first reported a position in TherapeuticsMD in Q2 2013 and held it in 8 quarters.
  • Sabby Management's TherapeuticsMD position peaked at $1.07M in Q1 2021.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.